Metabolic syndromes (MetS) and related cardiovascular diseases (CVDs) pose a serious threat to human health. MetS are metabolic disorders characterized by obesity, dyslipidemia, and hypertension, which increase the risk of CVDs’ initiation and development. Although there are many availabile drugs for treating MetS and related CVDs, some side effects also occur. Considering the low-level side effects, many natural products have been tried to treat MetS and CVDs. A five-cyclic triterpenoid natural product, oleanolic acid (OA), has been reported to have many pharmacologic actions such as anti-hypertension, anti-hyperlipidemia, and liver protection. OA has specific advantages in the treatment of MetS and CVDs. OA achieves therapeutic effects through a variety of pathways, attracting great interest and playing a vital role in the treatment of MetS and CVDs. Consequently, in this article, we aim to review the pharmacological actions and potential mechanisms of OA in treating MetS and related CVDs.

SUMOylation plays a crucial role in regulating gene expression by promoting interactions between transcription factors and corepressors. Daxx, a multifunctional scaffold protein, specifically recognizes and binds SUMOylated transcription factors through its SUMO-interacting motifs (SIMs), acting as a transcriptional corepressor. In this review, we systematically elucidate the structural basis of the interaction between Daxx and SUMO, revealing the synergistic mechanism by which Daxx SIM phosphorylation and SUMO acetylation dynamically regulate Daxx function. In promyelocytic leukemia nuclear bodies (PML NBs), phosphorylation of Daxx’s SIM enhances its binding to SUMOylated PML, leading to the sequestration and inactivation of Daxx within PML NBs. Conversely, SUMO acetylation disrupts the electrostatic interactions between SUMO and SIMs, prompting the release of Daxx from PML NBs and its translocation to the nucleoplasm, where it inhibits the activity of transcription factors such as ETS1, GR, and SMAD4. Daxx SIMs are common binding sites for the interaction between SUMOylated transcription factors and Daxx, and different SUMOylated transcription factors may compete to bind to Daxx, which cross-regulates cellular life activities. This mechanism highlights the dynamic regulation of Daxx subcellular localization and transcriptional repression by SUMO and PML NBs, providing valuable insights into understanding Daxx-mediated transcriptional repression.

Atherosclerosis (AS) is a cardiovascular disease characterized by diverse etiological factors and complex pathological mechanisms. In recent years, the role of long non-coding RNAs (lncRNAs) in AS has received increasing attention. Research shows that lncRNAs regulate key biological processes involved in AS, such as vascular endothelial function, proliferation and migration of vascular smooth muscle cells (VSMCs), macrophage polarization, and lipid metabolism, through various mechanisms, including epigenetic modification, transcriptional regulation, and post-transcriptional control. As important components of traditional medicine, Chinese herbal monomers and compounds have been found to modulate the expression of lncRNAs, thereby improving vascular endothelial function, reducing lipid deposition, and inhibiting inflammatory responses, ultimately exerting anti-atherosclerotic effects. This review systematically examines the role of lncRNAs in the disease mechanism of AS and summarizes recent advances in Traditional Chinese Medicine (TCM) interventions targeting lncRNA expression for the treatment of AS, offering new insights and directions for the prevention and management of AS with Chinese medicine.

Vascular smooth muscle cells (VSMCs) exhibit remarkable phenotypic plasticity, dynamically transitioning from a quiescent contractile state to a dedifferentiated synthetic phenotype that constitutes the fundamental cytological driver of pathological vascular remodeling in cardiovascular diseases (CVDs) including atherosclerosis, vascular restenosis, aortic dissection (AD), and vascular calcification (VC). Signal transducer and activator of transcription 3 (STAT3) operates as a master transcriptional and functional convergence node, integrating diverse upstream biochemical stimuli, neurohumoral factors, and biomechanical stressors to govern downstream gene regulatory networks. Aberrant STAT3 activation orchestrates VSMC phenotypic modulation, excessive proliferation, directional migration, programmed cell death involving apoptosis resistance and pyroptosis initiation, extracellular matrix (ECM) reorganization, and glycolytic metabolic reprogramming via canonical nuclear transcription and non-canonical subcellular actions. Here, we systematically delineate the modular structural organization, post-translational modifications, and negative regulatory feedback mechanisms of STAT3 in shaping VSMC functionality. Furthermore, we synthesize recent advances in pharmacological interventions by comprehensively categorizing therapeutic modalities into direct structural-domain inhibitors, upstream kinase-targeted indirect agents, bioactive natural products, and emerging clinical-stage translational candidates. Finally, we critically address translational hurdles regarding on-target systemic toxicities, and highlight site-specific vascular delivery systems alongside localized drug-eluting vascular devices to advance precision STAT3-targeted cardiovascular therapeutics.

Objectives: Endothelial apoptosis is a central event in atherosclerotic vascular injury, yet the contribution of the INO80 chromatin-remodeling subunit INO80E to this process remains unclear. This study examined whether INO80E is altered during atherosclerosis (AS)-associated endothelial injury and explored its functional role in ox-LDL-triggered apoptosis. Methods: Atherosclerotic mouse models were used to examine INO80E expression in vascular tissues, and ox-LDL-treated HUVECs were applied as an in vitro model of endothelial injury. The functional role of INO80E was evaluated using lentiviral overexpression and siRNA-mediated knockdown approaches, while apoptosis was measured by flow cytometry and TUNEL staining. Mechanistic experiments included co-immunoprecipitation, immunofluorescence, YY1 acetylation analysis, and pharmacological inhibition with the pan-HDAC inhibitor trichostatin A (TSA). In addition, YY1-silencing rescue experiments were performed in INO80E-overexpressing cells to determine whether YY1 contributes to the protective effect of INO80E against ox-LDL-induced endothelial apoptosis. Results: INO80E expression was reduced in the endothelial layer of ApoE^−/− aortas and in ox-LDL-treated HUVECs. INO80E overexpression attenuated ox-LDL-induced apoptosis and increased the Bcl-2/BAX ratio, whereas INO80E knockdown produced the opposite effect. INO80E colocalized with HDAC1, increased the HDAC1-YY1 association, decreased YY1 acetylation, and prolonged YY1 protein stability. TSA treatment weakened the anti-apoptotic phenotype associated with INO80E overexpression, and rescue experiments showed that YY1 knockdown partially reversed the INO80E overexpression-associated regulation of Bcl-2 and BAX. Conclusions: These findings suggest that INO80E protects endothelial cells from ox-LDL-induced apoptosis, at least in part by promoting HDAC-associated YY1 deacetylation and stabilization. The INO80E-HDAC1-YY1 pathway may represent a candidate protective mechanism in AS that requires further validation.